Ann Hards, PhD

Senior Consultant for
Regulatory Affairs

Ann Hards received her PhD in Biophysics and Genetics from the University of Colorado in 1985. She has been strategizing and negotiating new drug developments and approvals primarily in the employ of large pharma since 1990. During that 20-year period, she has had the primary responsibility for the worldwide (US, EU and +/-Japan) submission and prosecution of 6 new molecular entities (NME) dossiers and 7 major efficacy supplements resulting in 13 approvals. Among these, she has been responsible for the development and approval of multiple multi-billion dollar products including Lipitor®, Plavix®, Avapro®, etc.

It is self-evident that she is particularly well suited to shepherd new molecular entities, such as the Lohocla product, Kindolor, successfully through development and regulatory approval to join the ranks of some of today's better known brand names.

Some of the positions that Ann Hards has had prior to joining Lohocla Research Corporation include:

Parke-Davis Pharmaceutical Research Division of Warner Lambert 1990-1994
Regulatory Affairs Associate

Pharmacia Inc 1994-1995
Manager Regulatory Affairs, US Agent

Somatix Therapy Corporation 1995-1996
Associate Director Regulatory Affairs

Sanofi-Aventis (also Sanofi Pharmaceuticals Inc. and Sanofi-Synthelabo) 1996-2006
VP Regulatory Affairs
VP Clinical Investigations

ARCA Biopharma 2006-2008
Executive VP Regulatory Affairs

Bridging Health Matters, LLC 200-2010
President Pharmaceutical Development

Currently Ann also holds the position of Executive Vice President for Regulatory Affairs and Quality Assurance at Cleveland Biolabs, Inc., as well as her consulting role with Lohocla.

Lohocla
Research
Corporation